Our DNA:
hyaluronic acid

technologies
Fidia is among the very few companies worldwide with hyaluronic acid-based, FDA-approved products which are commercialised in the US, thus confirming the high quality standards, i.e. extreme purity of raw material and safety of the finished products, of Fidia's production capacities.

Being a natural component of the human body, hyaluronic acid (HA) is totally biocompatible, non-immunogenic and non-toxic.

Thanks to these unique characteristics, hyaluronic acid and its derivatives can be used in many areas of medicine, such as rheumatology, orthopaedics, tissue repair, aesthetics/dermatology, and surgery.

More than 50 years of research into this molecule have placed Fidia Farmaceutici at the forefront in the production of both natural and functionalized hyaluronic acid, using proprietary and validated manufacturing processes, with different ranges of molecular weight, according to the design characteristics of the finished products.

In addition, Fidia's breakthrough patented technology process allows to chemically modify the molecule in order to obtain suitable derivatives, with different physical and biological properties, to timprove the quality of care and best meet an individual patient's needs.
 

1963: launch of the first product ever based on HA (topical application)

1987: launch of the first products based on HA for intra-articular administration

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics